Perspectives on the cost of goods for hPSC banks for manufacture of cell therapies
This report summarized key issues contributing to the cost of preparing human pluripotent stem cell lines for use in cell therapy manufacturing. Stem cell banking experts from ten countries at a workshop session on ‘cost of goods’ for human pluripotent stem cells discussed at the Korea National Institutes of Health in Korea (25th September 2019) that was held by the International Stem Cell Banking Initiative (ISCBI). This report, publications the discussions that were done in the workshop and highlights and discussed the full range of costs and unexpected challenges on resources for the delivery of stocks of hPSCs suitable for use as starting materials in the manufacture of stem cell-based medicines. The experiences of global leaders from different national resource centers highlight issues to consider in cost management and the possibilities for reducing costs while moving into the clinical application stage.
منبع:
ارسال به دوستان